| è´§å· | å“牌 | 产å“åç§° | è§„æ ¼ | 包装ã€å‚è€ƒä»·æ ¼ | |
| D875507 | MACKLIN | 甲磺酸去é“胺 | ≥92.5% | 128å…ƒ/25mg; 358å…ƒ/100mg; 966å…ƒ/500mg; | 咨询 |
储å˜ï¼š-20℃ 状æ€ï¼šç™½è‰²åˆ°ç°ç™½è‰²ç²‰æœ« |
| D873692 | MACKLIN | 甲磺酸去é“胺 | ≥98% | 58å…ƒ/5mg; 185å…ƒ/25mg; 395å…ƒ/100mg; 1110å…ƒ/500mg; 1619å…ƒ/1g; 6599å…ƒ/5g; | 咨询 |
储å˜ï¼š-20℃ 状æ€ï¼šç™½è‰²åˆ°ç°ç™½è‰²å›ºä½“ |
| 454081 | J&K | Deferoxamine mesylate salt | 97% | 465元/250MG; 1559元/1G; 5456元/5G; | 咨询 |
åŸºæœ¬ä¿¡æ¯ | 分åå¼ | C26H52N6O11S | | 分åé‡ | 656.79 | | 熔点 | 145-149 | | MDLç¼–ç | MFCD00058605 | | Beilstein | 4122177 | | EINECS ç¼–å· | 205-314-3 | | å˜å‚¨æ¡ä»¶ | Freezer -20℃ |
å®‰å…¨ä¿¡æ¯ | 防范说明 | P262 | | WGK | 2 | | RTECS | UG5310000 |
|
| C46177 | Alfa Aesar | Deferoxamine mesylate | 95% | 4104元/1g; | 咨询 |
åŸºæœ¬ä¿¡æ¯ Ref# 46177 分åå¼ C25H48N6O8.CH4O3S 分åé‡ 292.13 |
| 252750 | Millipore | Deferoxamine Mesylate-CAS 138-14-7-Calbiochem | Parenteral iron chelating agent. Commonly used in therapy as a chelator of ferric iron in disorders of iron overload. | 1877.44元/1 G; | 咨询 |
产å“说明 一般æè¿° Parenteral iron chelating agent. Commonly used in therapy as a chelator of ferric iron in disorders of iron overload. Completely protects against dopamine-induced cell death. Has also been shown to interfere with hydroxyl radical formation, which mediates tissue damage in several disease states. Shows anti-proliferative effect on vascular smooth muscle cells in vitro and in vivo. Can also inhibit the oxidative chemistry of peroxynitrite by reaction of the hydroxamic acid moieties with trans-peroxynitrous acid. Parenteral iron chelating agent. Commonly used in therapy as a chelator of ferric iron in disorders of iron overload. Completely protects against dopamine-induced cell death. Has also been shown to interfere with hydroxyl radical formation, which mediates tissue damage in several disease states. Shows antiproliferative effects on vascular smooth muscle cells in vitro and in vivo. Can also inhibit the oxidative chemistry of peroxynitrite by reaction of the hydroxamic moieties with trans-peroxynitrous acid. 包装 1 g in Plastic ampoule è¦å‘Š Toxicity: Harmful & Carcinogenic / Teratogenic (E) 其他说明 Bergeron, R.J., et al. 1996. J. Med. Chem. 39, 1575. Ben-Shachar, D., et al. 1995. J. Neurochem. 64, 718. Denicola, A., et al. 1995. Free Radic. Biol. Med. 19, 11. Dzwigaj, S., and pererat, H., 1995. Free Radic. Res.14, 103. Dang, S., et al. 1994. Res. Commun. Mol. Pathol. Pharmacol. 86, 43. Porreca, E., et al. 1994. Arterioscler. Thromb. 14, 299. æ³•å¾‹ä¿¡æ¯ CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany åŸºæœ¬ä¿¡æ¯ | ç»éªŒ(实验)分åå¼ | C25H48N6O8 · xCH4O3S | | 分åé‡ | 560.68 (free base basis) | | MDLç¼–å· | MFCD00058605 |
äº§å“æ€§è´¨ | è´¨é‡æ°´å¹³ | 100 | | 测定 | 92.5-100% (TLC) | | å½¢å¼ | powder | | manufacturer/tradename | Calbiochem® | | å‚¨å˜æ¡ä»¶ | OK to freeze desiccated (hygroscopic) | | 颜色 | faint yellow | | 溶解性 | water: 50 mg/mL | | è¿è¾“ | ambient | | å‚¨å˜æ¸©åº¦ | 2-8℃ | | InChI | 1S/C25H48N6O8.CH4O3S/c1-21(32)29(37)18-9-3-6-16-27-22(33)12-14-25(36)31(39)20-10-4-7-17-28-23(34)11-13-24(35)30(38)19-8-2-5-15-26;1-5(2,3)4/h37-39H,2-20,26H2,1H3,(H,27,33)(H,28,34);1H3,(H,2,3,4) | | InChI key | IDDIJAWJANBQLJ-UHFFFAOYSA-N |
å®‰å…¨ä¿¡æ¯ | 储å˜åˆ†ç±»ä»£ç | 11 - Combustible Solids | | WGK | WGK 2 | | 闪点(F) | Not applicable | | 闪点(C) | Not applicable |
|
| D9533 | Sigma-Aldrich | Deferoxamine mesylate salt | ≥92.5% (TLC), powder | 1649.92å…ƒ/1 g; | 咨询 |
产å“说明 生化/生ç†ä½œç”¨ 去é“èƒºè¢«ç”¨ä½œä¸€ä¸ªç¼ºæ°§æ¨¡æ‹Ÿç‰©è´¨åŽ»ç¨³å®šä½Žæ°§è¯±å¯¼å› å1 (HIF-1)。 去é“胺通过抑制以HIF-1为é¶ç‚¹çš„脯氨酰羟化酶(PHDs)é™è§£æ¥ç¨³å®šHIF-1。 去é“胺的抑制机制å¯èƒ½æ˜¯é€šè¿‡Fe2+ 与酶活性所需的PHD活性ä½ç‚¹çš„螯åˆä½œç”¨è€Œå®žçŽ°çš„ã€‚ 一ç§é“螯åˆå‰‚ï¼Œå¸¸ç”¨äºŽç ”ç©¶ç»†èƒžå¢žæ®–å’Œå‡‹äº¡ã€‚ 体外 å’Œ 体内 å®žéªŒå‡æ˜¾ç¤ºå…¶å¯¹è¡€ç®¡å¹³æ»‘肌细胞具有抗增殖作用,并抑制G1期细胞的增殖。 æ®æŠ¥é“,它也诱导p53。 通过螯åˆé“诱导HL-60细胞凋亡。 ç»è¿‡1μM去é“胺处ç†48å°æ—¶åŽï¼ŒDNA明显æ–裂。 细胞ç»1μM去é“胺处ç†ä»…24å°æ—¶åŽå‘生凋亡;48å°æ—¶åŽè§‚å¯Ÿåˆ°æ ¸å塌。 ä¸€äº›ç ”ç©¶è¡¨æ˜Žï¼Œå®ƒå…·æœ‰æŠ—æ°§åŒ–æ€§èƒ½ï¼Œå¹¶ä¿æŠ¤ç»†èƒžå…å—H2O2诱导的æŸä¼¤ã€‚ åŸºæœ¬ä¿¡æ¯ | ç»éªŒ(实验)分åå¼ | C25H48N6O8 · CH4O3S | | 分åé‡ | 656.79 | | EC å· | 205-314-3 | | MDLç¼–å· | MFCD00058605 | | PubChem化å¦ç‰©è´¨ç¼–å· | 24894304 | | NACRES | NA.32 |
äº§å“æ€§è´¨ | è´¨é‡æ°´å¹³ | 200 | | 测定 | ≥92.5% (TLC) | | å½¢å¼ | powder | | 颜色 | white to off-white | | 溶解性 | H2O: 50 mg/mL | | å‚¨å˜æ¸©åº¦ | −20℃ | | SMILES string | CS(O)(=O)=O.CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN | | InChI | 1S/C25H48N6O8.CH4O3S/c1-21(32)29(37)18-9-3-6-16-27-22(33)12-14-25(36)31(39)20-10-4-7-17-28-23(34)11-13-24(35)30(38)19-8-2-5-15-26;1-5(2,3)4/h37-39H,2-20,26H2,1H3,(H,27,33)(H,28,34);1H3,(H,2,3,4) | | InChI key | IDDIJAWJANBQLJ-UHFFFAOYSA-N |
å®‰å…¨ä¿¡æ¯ | 储å˜åˆ†ç±»ä»£ç | 11 - Combustible Solids | | WGK | WGK 2 | | 闪点(F) | Not applicable | | 闪点(C) | Not applicable | | 个人防护装备 | Eyeshields, Gloves, type N95 (US) |
|
| D0160000 | | Deferoxamine mesylate salt | European Pharmacopoeia (EP) Reference Standard | 1572.27元/ ; | 咨询 |
产å“说明 一般æè¿° æœ¬äº§å“æŒ‰ç…§å‘行è¯å…¸çš„å‘行和规定æä¾›ã€‚æ”¯æŒæœ¬äº§å“的所有信æ¯ï¼ŒåŒ…括安全数æ®è¡¨å’Œä»»ä½•产å“ä¿¡æ¯ä¼ å•,都是在å‘行è¯å…¸çš„æŽˆæƒä¸‹å¼€å‘å’Œå‘布的。 如需进一æ¥ä¿¡æ¯å’Œæ”¯æŒï¼Œè¯·è®¿é—®çŽ°è¡Œè¯å…¸ç½‘站。 生化/生ç†ä½œç”¨ 一ç§é“螯åˆå‰‚ï¼Œå¸¸ç”¨äºŽç ”ç©¶ç»†èƒžå¢žæ®–å’Œå‡‹äº¡ã€‚ 体外 å’Œ 体内 å®žéªŒå‡æ˜¾ç¤ºå…¶å¯¹è¡€ç®¡å¹³æ»‘肌细胞具有抗增殖作用,并抑制G1期细胞的增殖。 æ®æŠ¥é“,它也诱导p53。 通过螯åˆé“诱导HL-60细胞凋亡。 ç»è¿‡1μM去é“胺处ç†48å°æ—¶åŽï¼ŒDNA明显æ–裂。 细胞ç»1μM去é“胺处ç†ä»…24å°æ—¶åŽå‘生凋亡;48å°æ—¶åŽè§‚å¯Ÿåˆ°æ ¸å塌。 ä¸€äº›ç ”ç©¶è¡¨æ˜Žï¼Œå®ƒå…·æœ‰æŠ—æ°§åŒ–æ€§èƒ½ï¼Œå¹¶ä¿æŠ¤ç»†èƒžå…å—H2O2诱导的æŸä¼¤ã€‚ 包装 å•使•°é‡ï¼š30 mgã€‚éšæ—¶å¯èƒ½æ”¹å˜ã€‚äº§å“æŒ‰ç…§å‘行è¯å…¸çš„规定交付。有关当å‰å•使•°é‡ï¼Œè¯·è®¿é—®EDQM对照å“目录。 æ³¨æ„ è¯·å‚è§ ç”±EDQMæä¾›çš„SDS。。 其他说明 å¯èƒ½é€‚用相应的销售é™åˆ¶ã€‚ åŸºæœ¬ä¿¡æ¯ | ç»éªŒ(实验)分åå¼ | C25H48N6O8 · CH4O3S | | 分åé‡ | 656.79 | | MDLç¼–å· | MFCD00058605 | | PubChem化å¦ç‰©è´¨ç¼–å· | 329798589 | | NACRES | NA.24 |
äº§å“æ€§è´¨ | ç‰çº§ | pharmaceutical primary standard | | manufacturer/tradename | EDQM | | application(s) | pharmaceutical (small molecule) | | æ ¼å¼ | neat | | SMILES string | CS(O)(=O)=O.CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN | | InChI | 1S/C25H48N6O8.CH4O3S/c1-21(32)29(37)18-9-3-6-16-27-22(33)12-14-25(36)31(39)20-10-4-7-17-28-23(34)11-13-24(35)30(38)19-8-2-5-15-26;1-5(2,3)4/h37-39H,2-20,26H2,1H3,(H,27,33)(H,28,34);1H3,(H,2,3,4) | | InChI key | IDDIJAWJANBQLJ-UHFFFAOYSA-N |
å®‰å…¨ä¿¡æ¯ | 储å˜åˆ†ç±»ä»£ç | 11 - Combustible Solids | | WGK | WGK 2 | | 闪点(F) | Not applicable | | 闪点(C) | Not applicable |
|
| Y0001934 | | Deferoxamine for system suitability | European Pharmacopoeia (EP) Reference Standard | 1548.8元/ ; | 咨询 |
产å“说明 一般æè¿° This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia. 生化/生ç†ä½œç”¨ 一ç§é“螯åˆå‰‚ï¼Œå¸¸ç”¨äºŽç ”ç©¶ç»†èƒžå¢žæ®–å’Œå‡‹äº¡ã€‚ 体外 å’Œ 体内 å®žéªŒå‡æ˜¾ç¤ºå…¶å¯¹è¡€ç®¡å¹³æ»‘肌细胞具有抗增殖作用,并抑制G1期细胞的增殖。 æ®æŠ¥é“,它也诱导p53。 通过螯åˆé“诱导HL-60细胞凋亡。 ç»è¿‡1μM去é“胺处ç†48å°æ—¶åŽï¼ŒDNA明显æ–裂。 细胞ç»1μM去é“胺处ç†ä»…24å°æ—¶åŽå‘生凋亡;48å°æ—¶åŽè§‚å¯Ÿåˆ°æ ¸å塌。 ä¸€äº›ç ”ç©¶è¡¨æ˜Žï¼Œå®ƒå…·æœ‰æŠ—æ°§åŒ–æ€§èƒ½ï¼Œå¹¶ä¿æŠ¤ç»†èƒžå…å—H2O2诱导的æŸä¼¤ã€‚ 包装 Unit quantity: 15 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue. 其他说明 Sales restrictions may apply. åŸºæœ¬ä¿¡æ¯ | ç»éªŒ(实验)分åå¼ | C25H48N6O8 · CH4O3S | | 分åé‡ | 656.79 | | MDLç¼–å· | MFCD00058605 | | NACRES | NA.24 |
äº§å“æ€§è´¨ | ç‰çº§ | pharmaceutical primary standard | | manufacturer/tradename | EDQM | | æ ¼å¼ | neat | | å‚¨å˜æ¸©åº¦ | 2-8℃ | | SMILES string | CS(O)(=O)=O.CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN | | InChI | 1S/C25H48N6O8.CH4O3S/c1-21(32)29(37)18-9-3-6-16-27-22(33)12-14-25(36)31(39)20-10-4-7-17-28-23(34)11-13-24(35)30(38)19-8-2-5-15-26;1-5(2,3)4/h37-39H,2-20,26H2,1H3,(H,27,33)(H,28,34);1H3,(H,2,3,4) | | InChI key | IDDIJAWJANBQLJ-UHFFFAOYSA-N |
å®‰å…¨ä¿¡æ¯ | 储å˜åˆ†ç±»ä»£ç | 11 - Combustible Solids | | WGK | WGK 2 | | 闪点(F) | Not applicable | | 闪点(C) | Not applicable |
|
| PHR3411 | Supelco | Deferoxamine mesylate | certified reference material, pharmaceutical secondary standard | 2000.81元/500 mg; | 咨询 |
产å“说明 一般æè¿° Pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards 生化/生ç†ä½œç”¨ 一ç§é“螯åˆå‰‚ï¼Œå¸¸ç”¨äºŽç ”ç©¶ç»†èƒžå¢žæ®–å’Œå‡‹äº¡ã€‚ 体外 å’Œ 体内 å®žéªŒå‡æ˜¾ç¤ºå…¶å¯¹è¡€ç®¡å¹³æ»‘肌细胞具有抗增殖作用,并抑制G1期细胞的增殖。 æ®æŠ¥é“,它也诱导p53。 通过螯åˆé“诱导HL-60细胞凋亡。 ç»è¿‡1μM去é“胺处ç†48å°æ—¶åŽï¼ŒDNA明显æ–裂。 细胞ç»1μM去é“胺处ç†ä»…24å°æ—¶åŽå‘生凋亡;48å°æ—¶åŽè§‚å¯Ÿåˆ°æ ¸å塌。 ä¸€äº›ç ”ç©¶è¡¨æ˜Žï¼Œå®ƒå…·æœ‰æŠ—æ°§åŒ–æ€§èƒ½ï¼Œå¹¶ä¿æŠ¤ç»†èƒžå…å—H2O2诱导的æŸä¼¤ã€‚ 分æžè¯´æ˜Ž These secondary standards offer multi-traceability to the USP, EP and BP primary standards, where they are available. 其他说明 This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis. 附注 To see an example of a Certificate of Analysis for this material enter LRAA6959(changes by product) in the Documents slot below. This is an example certificate only and may not be the lot that you receive. åŸºæœ¬ä¿¡æ¯ | ç»éªŒ(实验)分åå¼ | C25H48N6O8 · CH4O3S | | 分åé‡ | 656.79 | | MDLç¼–å· | MFCD00058605 |
äº§å“æ€§è´¨ | è´¨é‡æ°´å¹³ | 300 | | ç‰çº§ | certified reference material pharmaceutical secondary standard | | CofA | current certificate can be downloaded | | 包装 | pkg of 500 mg | | application(s) | pharmaceutical | | SMILES string | CS(O)(=O)=O.CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN | | InChI | 1S/C25H48N6O8.CH4O3S/c1-21(32)29(37)18-9-3-6-16-27-22(33)12-14-25(36)31(39)20-10-4-7-17-28-23(34)11-13-24(35)30(38)19-8-2-5-15-26;1-5(2,3)4/h37-39H,2-20,26H2,1H3,(H,27,33)(H,28,34);1H3,(H,2,3,4) | | InChI key | IDDIJAWJANBQLJ-UHFFFAOYSA-N |
å®‰å…¨ä¿¡æ¯ | 储å˜åˆ†ç±»ä»£ç | 13 - Non Combustible Solids | | WGK | WGK 2 | | 闪点(F) | Not applicable | | 闪点(C) | Not applicable |
|
| 1166003 | USP | Deferoxamine mesylate | United States Pharmacopeia (USP) Reference Standard | 3231.47元/300 MG; | 咨询 |
产å“说明 一般æè¿° This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia. 生化/生ç†ä½œç”¨ 一ç§é“螯åˆå‰‚ï¼Œå¸¸ç”¨äºŽç ”ç©¶ç»†èƒžå¢žæ®–å’Œå‡‹äº¡ã€‚ 体外 å’Œ 体内 å®žéªŒå‡æ˜¾ç¤ºå…¶å¯¹è¡€ç®¡å¹³æ»‘肌细胞具有抗增殖作用,并抑制G1期细胞的增殖。 æ®æŠ¥é“,它也诱导p53。 通过螯åˆé“诱导HL-60细胞凋亡。 ç»è¿‡1μM去é“胺处ç†48å°æ—¶åŽï¼ŒDNA明显æ–裂。 细胞ç»1μM去é“胺处ç†ä»…24å°æ—¶åŽå‘生凋亡;48å°æ—¶åŽè§‚å¯Ÿåˆ°æ ¸å塌。 ä¸€äº›ç ”ç©¶è¡¨æ˜Žï¼Œå®ƒå…·æœ‰æŠ—æ°§åŒ–æ€§èƒ½ï¼Œå¹¶ä¿æŠ¤ç»†èƒžå…å—H2O2诱导的æŸä¼¤ã€‚ 分æžè¯´æ˜Ž These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind. 其他说明 USP issued SDS can be found here. Sales restrictions may apply. åŸºæœ¬ä¿¡æ¯ | ç»éªŒ(实验)分åå¼ | C25H48N6O8 · CH4O3S | | 分åé‡ | 656.79 | | MDLç¼–å· | MFCD00058605 | | PubChem化å¦ç‰©è´¨ç¼–å· | 329749526 | | NACRES | NA.24 |
äº§å“æ€§è´¨ | ç‰çº§ | pharmaceutical primary standard | | manufacturer/tradename | USP | | application(s) | pharmaceutical (small molecule) | | æ ¼å¼ | neat | | å‚¨å˜æ¸©åº¦ | 2-8℃ | | SMILES string | CS(O)(=O)=O.CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN | | InChI | 1S/C25H48N6O8.CH4O3S/c1-21(32)29(37)18-9-3-6-16-27-22(33)12-14-25(36)31(39)20-10-4-7-17-28-23(34)11-13-24(35)30(38)19-8-2-5-15-26;1-5(2,3)4/h37-39H,2-20,26H2,1H3,(H,27,33)(H,28,34);1H3,(H,2,3,4) | | InChI key | IDDIJAWJANBQLJ-UHFFFAOYSA-N |
å®‰å…¨ä¿¡æ¯ | 储å˜åˆ†ç±»ä»£ç | 13 - Non Combustible Solids | | WGK | WGK 2 | | 闪点(F) | Not applicable | | 闪点(C) | Not applicable |
|
| BP987 | | Desferrioxamine mesilate | British Pharmacopoeia (BP) Reference Standard | 1916.08元/30 MG; | 咨询 |
产å“说明 一般æè¿° This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia. 生化/生ç†ä½œç”¨ 一ç§é“螯åˆå‰‚ï¼Œå¸¸ç”¨äºŽç ”ç©¶ç»†èƒžå¢žæ®–å’Œå‡‹äº¡ã€‚ 体外 å’Œ 体内 å®žéªŒå‡æ˜¾ç¤ºå…¶å¯¹è¡€ç®¡å¹³æ»‘肌细胞具有抗增殖作用,并抑制G1期细胞的增殖。 æ®æŠ¥é“,它也诱导p53。 通过螯åˆé“诱导HL-60细胞凋亡。 ç»è¿‡1μM去é“胺处ç†48å°æ—¶åŽï¼ŒDNA明显æ–裂。 细胞ç»1μM去é“胺处ç†ä»…24å°æ—¶åŽå‘生凋亡;48å°æ—¶åŽè§‚å¯Ÿåˆ°æ ¸å塌。 ä¸€äº›ç ”ç©¶è¡¨æ˜Žï¼Œå®ƒå…·æœ‰æŠ—æ°§åŒ–æ€§èƒ½ï¼Œå¹¶ä¿æŠ¤ç»†èƒžå…å—H2O2诱导的æŸä¼¤ã€‚ 包装 Unit quantity: 30 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity please visit British Pharmacopoeia 其他说明 Sales restrictions may apply. åŸºæœ¬ä¿¡æ¯ | ç»éªŒ(实验)分åå¼ | C25H48N6O8 · CH4O3S | | 分åé‡ | 656.79 | | MDLç¼–å· | MFCD00058605 |
äº§å“æ€§è´¨ | ç‰çº§ | pharmaceutical primary standard | | manufacturer/tradename | BP | | æ ¼å¼ | neat | | å‚¨å˜æ¸©åº¦ | 2-8℃ | | SMILES string | CS(O)(=O)=O.CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN | | InChI | 1S/C25H48N6O8.CH4O3S/c1-21(32)29(37)18-9-3-6-16-27-22(33)12-14-25(36)31(39)20-10-4-7-17-28-23(34)11-13-24(35)30(38)19-8-2-5-15-26;1-5(2,3)4/h37-39H,2-20,26H2,1H3,(H,27,33)(H,28,34);1H3,(H,2,3,4) | | InChI key | IDDIJAWJANBQLJ-UHFFFAOYSA-N |
å®‰å…¨ä¿¡æ¯ | 储å˜åˆ†ç±»ä»£ç | 11 - Combustible Solids | | WGK | WGK 2 | | 闪点(F) | Not applicable | | 闪点(C) | Not applicable |
|